An open label randomised controlled study in elderly subjects with previously untreated acute myelogenous leukaemia, comparing treatment groups randomised to receive daunorubicin and cytarabine or daunorubicin, cytarabine and PSC-833

ISRCTN ISRCTN11571826
DOI https://doi.org/10.1186/ISRCTN11571826
Secondary identifying numbers HO31; NTR360
Submission date
19/12/2005
Registration date
19/12/2005
Last edited
13/11/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Prof B. Löwenberg
Scientific

Erasmus Medical Center
Daniel den Hoed Cancer Center
Department of Hematology
P.O. Box 5201
Rotterdam
3008 AE
Netherlands

Phone +31 (0)10 4391598
Email b.lowenberg@erasmusmc.nl

Study information

Study designMulticentre, open label, randomised, active controlled, parallel group study
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study acronymHOVON 31 AML/Novartis PSC C 302-E-00
Study objectivesEvaluation of the effect of PSC-833 during induction treatment with daunorubicin and cytarabine.
Ethics approval(s)Received from the local medical ethics committee
Health condition(s) or problem(s) studiedAcute myeloid leukaemia (AML)
InterventionPatients with AML, meeting all eligibility criteria will be randomised on entry between:
Arm A: two induction cycles of daunorubicin (DNR) 45 mg/m^2/day, days 1 - 3 and cytarabine (Ara-C) 200 mg/m^2/day, days 1 - 7, or
Arm B: two induction cycles of DNR 35 mg/m^2/day, days 1 - 3; Ara-C 200 mg/m^2/day, days 1 - 7; and PSC-833 loading dose 2 mg/kg over 2 hours, followed by 10 mg/kg/day, days 1 - 3

Patients in CR will then be given one consolidation cycle without PSC-833 consisting of Ara-C, mitoxantrone and etoposide.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Daunorubicin, cytarabine, PSC-833
Primary outcome measureEvent-free survival
Secondary outcome measures1. Complete remission
2. Disease-free survival
3. Overall survival
4. Association between complete remission and expression of P-gp by AML-blasts
Overall study start date12/05/1997
Completion date17/02/1999

Eligibility

Participant type(s)Patient
Age groupSenior
SexBoth
Target number of participants400
Key inclusion criteria1. Aged greater than or equal to 60 years
2. Subjects who have a cytopathologically confirmed diagnosis of previously untreated AML (M0-M2 and M4-M7, FAB classification)
3. Subjects with secondary AML progressing from antecedent MDS are eligible if there has been no previous chemotherapy. Antecedent MDS is defined as any antecedent haematological disease of at least 4 months duration.
4. World Health Organization (WHO) performance status less than or equal to 2
5. Subjects have given written informed consent
Key exclusion criteria1. Cytopathologically confirmed central nervous system (CNS) infiltration. NB: in the absence of clinical suspicion of CNS involvement, lumbar puncture is not required.
2. Subjects have had previous Polycythemia Rubra Vera, primary myelofibrosis, are in blast cell crisis of chronic myeloid leukaemia or are M3 AML according to FAB classification
3. Subject has neurosensory toxicity greater than or equal to Grade 2 (NCIC Expanded CTC)
4. Subject has neurocerebellar toxicity greater than or equal to Grade 1 (NCIC Expanded CTC)
5. Subject is known to be positive for human immunodeficiency virus (HIV) type 1 antibody (testing to determine HIV antibody status is not necessary to be eligible)
6. Subject has impairment of hepatic or renal function as defined by the following baseline laboratory values:
6.1. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) greater than or equal to 2.5 times IULN
6.2. Alkaline phosphatase greater than or equal to 2.5 times IULN
6.3. Serum total bilirubin greater than or equal to 1.5 times IULN
6.4. Serum creatinine greater than or equal to 1.5 times IULN after adequate hydration
7. Subject is currently receiving treatment with any of the agents listed in the protocol if treatment cannot be discontinued at the specified time relative to PSC-833 administration. All of the drugs listed are well substantiated to interact with cyclosporin A.
8. Subject has had major surgery within 2 weeks of study entry
9. Subject has received investigational therapy within 30 days of study entry
10. Subject has known hypersensitivity to cyclosporin A
11. Subject has received prior radiotherapy within 4 weeks of study entry
12. Subject is less than 5 years free of another primary malignancy with the exception of basal cell carcinoma of the skin and stage 1 cervical carcinoma
13. Subject has previously been treated with chemotherapy for AML
14. Subject has concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension etc.)
15. Subject has a psychological, intellectual or sensory dysfunction which is likely to impede their ability to understand and comply with study requirements
16. Subject had a myocardial infarction within the last 6 months, has symptomatic ischaemic heart disease, congestive heart failure or other uncontrolled coronary disease
Date of first enrolment12/05/1997
Date of final enrolment17/02/1999

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Erasmus Medical Center
Rotterdam
3008 AE
Netherlands

Sponsor information

Novartis Pharma AG (Switzerland)
Industry

-
Basel
CH-4002
Switzerland

ROR logo "ROR" https://ror.org/02f9zrr09

Funders

Funder type

Research organisation

Dutch Haemato-Oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON) (The Netherlands)

No information available

Novartis Pharma B.V. (The Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article Results 15/10/2005 Yes No